CLYM
Climb Bio, Inc.
Biotechnology · Healthcare · United States
10.25
close · 2026-10-30
value
84
cheaper than peers84
quality
93
stronger fundamentals93
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, 1 year ago | -2.6% | 83 |
| earnings yield, latest year | -8.6% | 78 |
| cash flow yield, 2 years ago | -3.5% | 78 |
| earnings yield, 2 years ago | -12.7% | 70 |
| earnings yield, 3 years ago | -16.8% | 68 |
| cash flow yield, latest year | -9.3% | 66 |
| earnings yield, 1 year ago | -14.9% | 63 |
| cash flow yield, 3 years ago | -6.3% | 63 |
| price to book | 2.46× | 50 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 0.3% | 89 |
| return on equity | -30.9% | 85 |
| operating margin | 0.0% | 50 |
3 of 4 measures available
Facts
| market cap | $589M |
| free cash flow | -$34.7M |
| employees | 28 |
| first trade | 2021-08-10 |
| next earnings | not reported |
| fundamentals updated | 2026-07-27 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.88 | -1.53 | -1.30 | -1.72 |
| free cash flow | -$54.5M | -$15.6M | -$20.6M | -$37.4M |
| net income | -$59.9M | -$73.9M | -$35.1M | -$45.2M |
| revenue | $0 | $0 | $0 | $0 |
| unusual items | -$291,000 | -$51.7M | $536,000 | -$1.5M |